MDCXW:NSD-Medicus Pharma Ltd. Warrant (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 2.5

Change

0.00 (0.00)%

Market Cap

N/A

Volume

4.65K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Medicus Pharma Ltd., a biotech/life sciences company, focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. It develops SkinJect, with an indication for basal cell carcinoma that is drug device combination product using novel dissolvable microneedle arrays for the treatment of non-melanoma skin cancers. The company was founded in 2015 and is headquartered in Toronto, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-15 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

N/A

USD 218.30B
AMGN Amgen Inc

N/A

USD 154.96B
GILD Gilead Sciences Inc

N/A

USD 139.89B
SNY Sanofi ADR

N/A

USD 122.86B
BIIB Biogen Inc

N/A

USD 19.51B
GRFS Grifols SA ADR

N/A

USD 6.70B
AMRN Amarin Corporation PLC

N/A

USD 0.24B
MIRA MIRA Pharmaceuticals, Inc. Com..

N/A

USD 0.02B
SCLX Scilex Holding Company

N/A

N/A
SCLXW Scilex Holding Company

N/A

N/A

ETFs Containing MDCXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 186.80% 91% A- 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 186.80% 91% A- 97% N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector